检索结果-内蒙古大学图书馆

Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination-China,2013-2021

China CDC weekly 2024年第50期6卷 1325-1330页

作者： Yuyang Xu Keli Li Yan Li Yuan Li Lina Zhang Chunxiang Fan Minrui Ren Zundong Yin Department of Expanded Program on Immunization Hangzhou Center for Disease Control and PreventionHangzhou CityZhejiang ProvinceChina National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases(NITFID) National Immunization ProgramChinese Center for Disease Control and PreventionBeijingChina

What is already known about this topic?From 2010 to 2012,the incidence of adverse vaccine reactions from meningococcal vaccine(MenV)in China ranged from 8.46 to 56.30 per 100,000 *** is added by this report?From 2013 to 2021,the overall reported rate of adverse events following immunization(AEFI)of five types of market-authorized MenV-containing vaccines in China was 37.87 per 100,000 doses administered,with a reported incidence of adverse vaccine reactions of 37.39 per 100,000 *** reported incidence of adverse vaccine reactions was comparable to that from 2010 to 2012 and perceived to be within an acceptable *** rare vaccine reactions were allergic rashes,and most of these cases were transient and *** are the implications for public health practice?In China,the incidence of AEFI was very low,and serious abnormal reactions were extremely *** should continue to carry out technical training for vaccinators and on-site treatment capabilities to improve emergency treatment for anaphylactic shock and other serious events and ensure the continued safety of vaccination.

关键词： doses vaccine treatment

来源：评论

学校读者我要写书评

暂无评论

Investigation of a cross-border measles outbreak in Moroto District, northeastern Uganda, March–September, 2024

引用

Discover public health 2025年第1期22卷 1-15页

作者： Mfitundinda, Emmanuel Migisha, Richard Namusisi, Annet Mary Wenani, Daniel Kwesiga, Benon Ayeerwot, Ruth Korobe, Emmanuel Ssekandi, Druscillah Bulage, Lilian Ario, Alex Riolexus Uganda Public Health Fellowship Program Uganda National Institute of Public Health Kampala Uganda Karamoja Regional Emergency Operations Centre Moroto Uganda Moroto District Local Government Moroto Uganda Uganda National Expanded Program on Immunization Ministry of Health Kampala Uganda

Background: On June 26, 2024, Ministry of Health was notified of a measles outbreak in Moroto District, northeastern Uganda, which had already resulted in four deaths. We investigated to assess magnitude of the outbreak, identify its source and risk factors, and recommend evidence-based control and prevention measures. Methods: We defined a suspected case as onset of fever and maculopapular rash, and ≥ 1 of cough, coryza, or conjunctivitis in a resident of Moroto District from March 15 to September 22, 2024. A confirmed case was a suspected case with a positive measles-specific IgM test. We identified cases using health facility records and active case search within the health facilities. We conducted a hospital-based case–control study with a 1:2 ratio. Controls were children admitted to the pediatric ward with an alternative diagnosis but no history of fever, rash, or conjunctivitis. We used logistic regression to identify risk factors. We estimated the vaccine effectiveness (VE) from adjusted odds ratio (aOR) associated with vaccination (VE = 1-aOR) % and vaccination coverage (VC) from percentage of vaccinated controls. Results: We identified 290 case-patients (275 suspected and 15 confirmed), with 6 deaths (case fatality rate [CFR] = 2%). The index case-patient was a 10-month-old child who had returned from the Western Turkana Region of Kenya, where a measles outbreak was ongoing. The overall attack rate (AR) was 19/10,000. Lotisan Sub-county (AR = 50/10,000) and children < 1 year (AR = 194/10,000) were the most affected. Being vaccinated was protective (aOR = 0.11, 95% CI 0.03–0.4). Visiting a health facility 7–21 days before the onset of rash (aOR = 3.8, 95% CI 1.3–11) and having malnutrition (aOR = 6.1, 95% CI 1.3–27) increased the odds of contracting measles. Estimated VC was 67% and VE was 89% (95% CI 60–97%). Conclusion: The outbreak was likely imported from Kenya, and was propagated by low vaccination coverage, and healthcare visits within the exposure pe

关键词： Cross-border health surveillance Disease outbreak Measles Uganda Vaccine-coverage Vaccine-effectiveness

来源：评论

学校读者我要写书评

暂无评论

Willingness of the General Public to Receive the COVID-19 Vaccine During a Second-Level Alert——Beijing Municipality,China,May 2020

引用

China CDC weekly 2021年第25期3卷 531-537页

作者： Rui Ma Luodan Suo Li Lu Xinghuo Pang Division of Expanded Program of Immunization(EPI) Beijing Center for Disease Control and Prevention/Beijing Center for Preventive Medicine ResearchBeijingChina

Summary What is already known on this topic?Preclinical trials showed the effectiveness of domestic inactivated vaccine candidates for coronavirus disease 2019(COVID-19).However,it is necessary to evaluate the willingness of the public to receive future domestic vaccines and to understand factors associated with willingness at the early stages of vaccine development.

关键词： COV Public Summary

来源：评论

学校读者我要写书评

暂无评论

Risk factors for pertussis among children hospitalized for pertussis during 2016-2017, in Guizhou Province of China: a case-control study

引用

Global Health Journal 2021年第2期5卷 97-101页

作者： Feng Jiang Keli Li Guangpeng Tang Yan Huang Guizhou Center for Disease Control and Prevention Institute of Expanded Programme on ImmunizationGuiyang 550004China Chinese Center for Disease Control and Prevention Center for National Immunization ProgramBeijing 102206China Guizhou Centre for Disease Control and Prevention Institute of Communicable Disease Control and PreventionGuiyang 550004China

Aim:Pertussis is a respiratory tract infection,the vaccine for which was introduced in the expanded programme on immunization(EPI)in Guizhou Province of China(hereafter referred as Guizhou)in the *** vaccine rapidly decreased incidence rates of pertussis in the province,however,despite the wide high coverage of the diphtheria,tetanus and acellular pertussis(DTaP)combined vaccine,there has been a resurgence of pertussis since *** with this recent increase in disease transmission,risk factors for pertussis infection have not been evaluated in *** aimed to provide information on pertussis risk factors and insight on designing targeted pertussis control policies and measures through this ***:A 1:2 matched retrospective case-control study was conducted between 2016 and 2017,involving infants and children younger than 6 years old and parents of the *** enrolled cases included clinical and laboratory confirmed pertussis cases according to the WHO-recommended pertussis *** were selected from children in the same neighborhood who were not diagnosed with pertussis prior to our investigation and did not exhibit any clinical manifestations of ***:The household size[Matched odds ratio(OR_(m)=1.4,95%confidence interval(Cl):1.1-1.7]and household members with antecedent cough(OR_(m)=3.6,95%CI:1.8-7.2)were significantly associated with their child’s pertussis *** parents’occupations were significantly associated with their child’s pertussis onset(ORm=9.4,95%CI:1.6-54.8,for mother side;ORm=4.5,95%CI:1.2-16.5,for father side),when they worked in the business and/or service *** family members with a history of cough was an independent risk factor for pertussis[Adjusted odds ratio(AOR)=43.6,95%CI:2.7-694.0].Besides,the parents’demographic characteristics and DTaP doses were not found to be independent ***:Household exposure is an important risk factor for pertussis infection in infa

关键词： Pertussis risk factors Household exposure Guizhou province China Pertussis resurgence Diphtheria Tetanus and acellular pertussis combined vaccine

来源：评论

学校读者我要写书评

暂无评论

The Contribution of Periodic Intensification of Routine immunization to Vaccination Coverage and Disease Surveillance in the South West Region of Cameroon amid Sociopolitical Crisis and Covid-19 Outbreak in 2020

Research Square

引用

Research Square 2021年

作者： Njoh, Andreas Ateke Saidu, Yauba Bachir, Hassan Ben Ndoula, Shalom Tchokfe Mboke, Eric Nembot, Raoul Tambasho, Azu Chrakoh Abizou, Messang Blandine Seungue, Judith Mbanga, Clarence Mbome, Victor Njie Expanded Program on Immunization Cameroon Clinton Health Access Initiative Cameroon MoPH: Ministry of Public Health Cameroon Expanded Program on Immunization Cameroon Faculty of Medicine and Biomedical Sciences Cameroon University of Buea Faculty of Health Sciences Cameroon

Introduction: The Southwest Region of Cameroon has been hit by an armed conflict for over half a decade now, which has negatively affected routine immunization and disease surveillance activities in the region. This negative effect was further acerbated by the Covid-19 pandemic, which alongside the conflict caused thousands of children to miss out on life saving vaccinations. Herein, we present the contribution of periodic intensification of routine immunization, in improving immunization and surveillance activities amid crises. Method Periodic intensification of routine immunization (PIRI) and surveillance was carried out in three rounds per health district. Prior to the intervention, the security profile of each district involved was reviewed. Data for this study was extracted on vaccination and surveillance activities from the District Health Information Software and from monthly regional reports for 2019 and 2020. Results In total 54,242 persons were vaccinated in the SW region following these interventions. An increase in performance was observed in all 18 health districts of the region in 2020, with both DPT-3 and OPV-3 coverage rising by 28% points. Similarly, the proportion of health districts that investigated at least a case of acute flaccid paralysis increased by 83%, rising from just 3 districts in 2019 to 18 in 2020. Conclusion PIRI was a very useful approach to improve both vaccination coverage and surveillance indicators in this region amidst the ongoing conflict and Covid-19 pandemic. © 2021, CC BY.

关键词： immunization

来源：评论

学校读者我要写书评

暂无评论

Adverse events Following immunization with Fractional one-fifth and one-half doses of Yellow Fever Vaccine compared to full dose in children 9–23 months old in Uganda — Preliminary report

引用

International Journal of Infectious Diseases 2025年 152卷 107485-107485页

作者： Twinomuhwezi, Ms Ellon Casey, Dr. Rebecca M Tumwine, Dr. Conrad Namwanje, Ms Angela Nakato, Dr. Winfred Nansozi Sekiziyivu, Dr. Arthur Brian Najjengo, Mrs Marjorie Sserunga Lubega, Dr. Irene Ampeire, Dr. Immaculate Tuttle, Ms Alexandra Chub, Ms Susan Y. Chub Susan Y Doshi, Ms Reena H. H Kambugu, Dr. Andrew Gidudu, Dr. Jane F Infectious Diseases Institute Makerere College Of Health Sciences Global Immunization Division Centers for Disease Control and Prevention Expanded Program on Immunization Ministry of Health Kampala Uganda

BackgroundIn 2016, the World Health Organization recommended that a fractional dose of yellow fever vaccine could be used in persons 2 years of age or older in response to an emergency situation that resulted in a global shortage of available yellow fever vaccine. However, this recommendation did not extend to the youngest age group licensed for yellow fever vaccine as no published data were available on the use or safety of fractional dose yellow fever vaccination among children aged 9–23 months. We conducted a single-blind randomized controlled trial comparing the immunogenicity and safety of fractional one-fifth and one-half doses of Bio-Manguinhos 17DD yellow fever vaccine with full dose in children 9-23 months old in Uganda. In this paper, we present the interim analysis on safety. MethodsChildren aged 9–23 months presenting for routine well-child services were recruited for inclusion at one of three study sites. We collected data on all adverse event(s) following immunization (AEFI) during active AEFI surveillance for 28 days post-vaccination using multiple data collection tools including a home diary card with an objective measurement of fever. An independent team from the Uganda national AEFI Committee investigated and classified serious AEFI (SAE) according to Brighton Collaboration Criteria. ResultsAmong 1053 enrolled children, 672 (64%) were reported to have a non-serious AEFI (NSAE) and 18 (2%) were reported to have a SAE. The most commonly reported AEFI were diarrhoea, fever and rash, each reported by 355 (34%), 338 (33%) and 188 (18%) participants, respectively. Among 18 participants with SAE, eight were reported to have seizures and five were hospitalised for seizures or other causes (respiratory symptoms, gastrointestinal illness, malaria). Four SAEs (deaths) occurred >28 days after vaccination. There were no reported cases of pre-specified or vaccine-related SAEs. We observed no significant difference in frequency or severity of adverse event among

关键词：

来源：评论

学校读者我要写书评

暂无评论

Prevalence of Precancerous Lesions Based on Digital Cervicography with VIA/VILI among Women Positive for High-Risk Human Papillomavirus Serotypes: A Screening Center-Based Study in Cameroon

引用

Open Journal of Obstetrics and Gynecology 2024年第6期14卷 967-978页

作者： Jeffrey-Lewis Nzang Cliford Ebontane Ebong Simon Manga Florence Manjuh Félix Essiben Isidore Tompeen Judith Seungue Serge Robert Nyada Jeanne Hortence Fouedjio Ymele Fouelifack Julius Sama Dohbit Kloukanmey Zonal Hospital Mdecins Sans Frontires Kloukanmey Benin Faculty of Medicine and Biomedical Sciences University of Yaound 1 Yaound Cameroon Gynecology and Obstetrics Unit Central Hospital of Yaound Yaound Cameroon Womens Health Program Cameroon Baptist Convention Health Services Yaound Cameroon Department of Obstetrics and Gynaecology Gyneco-Obstetric and Pediatric Hospital of Yaound Yaound Cameroon Expanded Program of Immunization Ministry of Health Yaound Cameroon Department of Obstetrics and Gynaecology Gynaecological Endoscopic Surgery and Human Reproductive Teaching Hospital Yaounde Cameroon Department of Obstetrics and Gynaecology University of Dschang Dschang Cameroon Higher Institute of Medical Technology Nkolondom Yaound Cameroon

Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a

关键词： High-Risk Human Papillomavirus Precancerous Digital Cervicography VIA/VILI Serotype

来源：评论

学校读者我要写书评

暂无评论

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial

引用

The Lancet 2021年第10269期397卷 119-127页

作者： Juan-Giner, Aitana Kimathi, Derick Grantz, Kyra H Hamaluba, Mainga Kazooba, Patrick Njuguna, Patricia Fall, Gamou Dia, Moussa Bob, Ndeye S Monath, Thomas P Barrett, Alan D Hombach, Joachim Mulogo, Edgar M Ampeire, Immaculate Karanja, Henry K Nyehangane, Dan Mwanga-Amumpaire, Juliet Cummings, Derek A T Bejon, Philip Warimwe, George M Grais, Rebecca F Epicentre Paris France Kenya Medical Research Institute—Wellcome Trust Research Programme Kilifi Kenya Centre for Tropical Medicine & Global Health University of Oxford Oxford United Kingdom Department of Biology University of Florida Gainesville FL United States Emerging Pathogens Institute University of Florida Gainesville FL United States Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore MD United States Epicentre Mbarara Research Centre Mbarara Uganda Institut Pasteur Dakar Dakar Senegal Crozet BioPharma LLC Devens MA United States Sealy Institute for Vaccines Sciences and Department of Pathology University of Texas Medical Branch Galveston TX United States Immunization Vaccines & Biologicals WHO Geneva Switzerland Department of Community Health Mbarara University of Science & Technology Mbarara Uganda Expanded Program on Immunization Ministry of Health Kampala Uganda

Background: Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared with standard dose of four WHO-prequalified yellow fever vaccines produced from three substrains. Methods: We did this randomised, double-blind, non-inferiority trial at research centres in Mbarara, Uganda, and Kilifi, Kenya. Eligible participants were aged 18–59 years, had no contraindications for vaccination, were not pregnant or lactating, had no history of yellow fever vaccination or infection, and did not require yellow fever vaccination for travel. Eligible participants were recruited from communities and randomly assigned to one of eight groups, corresponding to the four vaccines at standard or fractional dose. The vaccine was administered subcutaneously by nurses who were not masked to treatment, but participants and other study personnel were masked to vaccine allocation. The primary outcome was proportion of participants with seroconversion 28 days after vaccination. Seroconversion was defined as post-vaccination neutralising antibody titres at least 4 times pre-vaccination measurement measured by 50% plaque reduction neutralisation test (PRNT₅₀). We defined non-inferiority as less than 10% decrease in seroconversion in fractional compared with standard dose groups 28 days after vaccination. The primary outcome was measured in the per-protocol population, and safety analyses included all vaccinated participants. This trial is registered with ***, NCT02991495. Findings: Between Nov 6, 2017, and Feb 21, 2018, 1029 participants were assessed for inclusion. 69 people were ineligible, and 960 participants were enrolled and randomly assigned to vaccine manufacturer and dose (120 to Bio-Manguinhos-Fiocruz standard dose, 120 to Bio-Manguinhos-Fiocruz fraction

关键词：

来源：评论

学校读者我要写书评

暂无评论

Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey

引用

Vaccine 2025年 60卷 127323页

作者： Andreas Ateke Njoh Jerome Nyhalah Dinga Eugene Justine Kongnyuy Tchokfe Shalom Ndoula Adidja Amani Ibrahima Madaina Muluh Ngwe Sonnet Ticha Messang Blandine Abizou Yauba Saidu Hassan Ben Bachir Laurent Cleenewerck de Kiev Expanded Program on Immunization Ministry of Public Health Yaounde Cameroon School of Global Health and Bioethics Euclid University Bangui Central African Republic Michael Gahnyam Gbeugvat Foundation Buea Cameroon Biotechnology Unit University of Buea Buea Cameroon Faculty of Medicine and Biomedical Sciences University of Yaounde 1 Yaounde Cameroon Cameroon Clinton Health Access Initiative Cameroon Department of Health Promotion Ministry of Public Health Yaounde Cameroon

Introduction Malaria is a life-threatening mosquito-borne disease. This significant public health problem disproportionately affects people in Africa. Despite investments in existing vector control and curative treatments, malaria remains the first infant-child morbidity and mortality cause, with 11,000 annual deaths in Cameroon. However, there are effective vaccines against the disease. So, this study sought to evaluate vaccine acceptance and related factors to guide the vaccine rollout. Method This nationwide cross-sectional survey collected data from December 2023 to January 2024 using an online and in-person questionnaire. The chi-square test identified the malaria vaccine acceptance elements, and multiple logistic regression depicted factors linked to vaccine acceptance. SPSS enabled analysis, and a p -value <0.05 was considered significant. Microsoft Excel 365 eased the elaboration of charts and tables. Result Data from 2025 participants indicated a 91 % malaria vaccine acceptance. This rate varied from 78 % in the Littoral to 94 % in the Far North and South West regions. Factors that favor vaccine acceptance include a history of severe malaria (OR = 1.4, 95 %CI: 1.0–1.8, p = 0.03), awareness of the availability of the malaria vaccine for infants (OR = 1.4, 95 %CI: 1.0–2.0, p = 0.03), and working in the vaccination service (OR = 3.8, 95 %CI: 2.7–5.3, p < 0.01). Elements reported for vaccine hesitancy include fear of unsafe and negative rumors about the vaccine. Conclusion People in Cameroon are willing to get their children vaccinated against malaria. However, following regional acceptance disparities and identified hesitancy points, it is crucial to reinforce communication to address population groups, doubts, and rumors about vaccines to ensure optimal uptake in the country's regions during the malaria vaccine rollout.

关键词： Associated factors Cameroon Malaria vaccine Vaccine acceptance Vaccine hesitancy

来源：评论

学校读者我要写书评

暂无评论

Measles Virus IgG Avidity Assay for Use in Identification of Measles Vaccine Failures in Tianjin, China

引用

Biomedical and Environmental Sciences 2019年第11期32卷 804-811页

作者： DING Ya Xing MAO Nai Ying ZHANG Yan LEI Yue GAO Zhi Gang XU Wen Bo ZHANG Ying Department of Expanded Program Immunization Tianjin Center for Diseases Control and PreventionTianjin 300011China National Institute for Viral Disease Control and Prevention Chinese Center for Diseases Control and PreventionBeijing 102206China Department of Viral Laboratory Tianjin Center for Diseases Control and PreventionTiannin 300011China Institute for Infectious Diseases Control and Prevention Tianjin Center for Diseases Control and PreventionTianjin 300011China

Objective To identify measles vaccine failures in Tianjin, China using a measles virus Ig G avidity *** The China Information System for Disease Control and Prevention(CISDCP) was used to collect information about measles cases and blood specimens in Tianjin from 2013 to 2015. Measlesspecific Ig M and Ig G antibodies were detected using Enzyme-Linked Immunosorbent Assay(ELISA).Avidity testing for measles Ig G was performed using a commercial enzyme immunoassay(EIA).Results A total of 284 confirmed measles cases were identified. Of this total, 262(92.25%) were in patients aged ≥ 20 years. High avidity was exhibited in 172(60.56%) cases, while 80(28.17%) cases demonstrated low avidity. High avidity was detected in only 21.43% of cases in patients aged < 1 *** proportion of high avidity increased with age, and was significantly higher in patients aged 30–39 years at 70.07%(χ~2 = 17.27, P = 0.002). Of the 52 measles cases in patients with a history of vaccinations,41(78.85%) cases showed high avidity, indicating secondary vaccine failures(SVF). In these vaccinations,there was no significant difference(P > 0.05) in clinical severity between high avidity and low avidity cases. However, regardless of vaccination status, clinical severity was significantly lower in high avidity cases(P < 0.001) than in low avidity cases. The percentages of positive measles Ig M results in high avidity and low avidity cases were 66.28% and 91.25%, respectively. Geometric Mean Concentration(GMC) was significantly lower in high avidity cases at 33.73 U/m L, compared to 166.07 U/m L in low avidity *** Low clinical severity and inconclusive Ig M antibody results are more likely in high avidity measles cases. Measles cases were more common in adults. Therefore, a further dose of vaccines should be recommended for 30–39 years in Tianjin.

关键词： Measles IgG avidity China Primary vaccine failures Secondary vaccine failures

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：